13F Holdings
中文EN

FBIO Fortress Biotech, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1429260 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY12.3%
TTM net income YoY2,411.2%
TTM EPS YoY2,016.7%
Revenue 3-yr CAGR-4.7%
Net income 3-yr CAGR—

Margins

Gross margin66.2%
Operating margin-42.5%
Net margin143.0%
FCF margin—
EBITDA margin-41.9%

Returns

ROE92.8%
ROA43.4%
ROIC (approx.)-227.3%
Asset turnover0.30x

Leverage & solvency

Liabilities / assets36.8%
Debt / equity0.00x
Current ratio2.93x
Interest coverage-3.17x

Cash quality & payout

Operating cash flow / net income1.26x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$63.26M$57.67M$84.51M$75.74M$68.79M
Cost of revenue$20.92M$20.88M$22.89M$30.77M$32.08M
Gross profit$42.34M$36.80M$61.62M$44.97M$36.71M
R&D expense$11.90M$56.63M$101.75M$134.88M$128.87M
SG&A expense$96.40M$87.73M$90.98M$113.66M$86.84M
Operating income-$70.22M-$110.38M-$142.34M-$203.56M-$188.54M
Interest expense$10.11M$13.53M$15.31M$12.48M$15.31M
Pretax income-$33.53M-$120.54M-$153.63M-$213.46M-$164.35M
Income tax-$620,000$312,000$521,000$449,000$473,000
Net income$6.82M-$46.00M-$60.64M-$86.58M-$64.70M
EBITDA-$69.82M-$109.34M-$140.11M-$200.46M-$185.91M
EPS (basic)-0.07-2.69-8.47-15.97-0.79
EPS (diluted)-0.07-2.69-8.47-15.97-0.79
Weighted avg. shares (diluted)27.90M20.78M8.11M5.92M81.70M
Balance sheet
Cash & equivalents$79.38M$58.81M$83.36M$180.95M$307.96M
Receivables$29.78M$10.23M$15.22M$28.21M$23.11M
Inventory$9.62M$14.43M$10.21M$14.16M$9.86M
Current assets$123.84M$90.37M$117.02M$230.43M$346.46M
PP&E, net$2.52M$3.26M$6.50M$13.02M$15.07M
Intangibles$27.61M$31.86M$20.29M$27.20M$12.55M
Total assets$185.55M$144.22M$167.53M$294.30M$396.50M
Current liabilities$49.74M$71.40M$84.91M$127.72M$101.04M
Long-term debt$54.49M$57.96M$60.86M$91.73M$42.94M
Total debt$54.49M$57.96M$60.86M$91.73M$42.94M
Total liabilities$123.36M$145.87M$165.94M$244.28M$170.63M
Shareholders' equity$49.87M$22.74M$22.54M$41.72M$108.67M
Net debt-$24.89M-$853,000-$22.51M-$89.22M-$265.03M
Shares outstanding31.36M27.91M15.09M7.37M101.44M
Cash flow statement
Operating cash flow-$65.78M-$80.19M-$128.22M-$179.40M-$116.54M
Capital expenditure—$0$63,000$2.71M$4.57M
Free cash flow—-$80.19M-$128.29M-$182.12M-$121.11M
Investing cash flow$10.12M-$15.00M-$2.10M-$22.93M$40.51M
Financing cash flow$77.44M$70.64M$32.74M$75.32M$148.99M
Depreciation & amortization$403,000$1.04M$2.23M$3.11M$2.63M
Stock-based compensation$28.74M$32.62M$17.03M$22.99M$19.49M
Dividends paid$664,000$694,000$736,000$749,000$749,000

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.